safety profile
Structure Therapeutics’ oral obesity drug shows competitive early data vs Novo and Lilly; Ascletis reports early obesity results
Structure Therapeutics; GSBR-1290; oral GLP-1; obesity pill; weight-loss drug; Novo Nordisk; Eli Lilly; Wegovy; Ozempic; Zepbound; Ascletis; ASC41; ASC42; phase 1 trial; phase 2 trial; weight reduction; safety profile
AstraZeneca Makes Strong Case for Baxdrostat with Detailed 24-Hour Data in Resistant Hypertension Trial
AstraZeneca; baxdrostat; resistant hypertension; phase III trial; aldosterone synthase inhibitor; blood pressure; 24-hour data; ambulatory blood pressure; safety profile
Arcturus Therapeutics Stock Crashes 60% on Underwhelming mRNA Cystic Fibrosis Drug Results
Arcturus Therapeutics; ARCT-032; cystic fibrosis; mRNA therapy; stock crash; clinical trial results; lung function; FEV1; safety profile
Sanofi Challenges Novartis’ Dominance with Clinically Meaningful Pancreatic Tumor Data from AlphaMedix Phase II Trial
Sanofi; Novartis; radiopharma; AlphaMedix; Orano Med; gastroenteropancreatic neuroendocrine tumors; GEP-NETs; radioligand therapy; Phase II clinical trial; progression-free survival; overall survival; safety profile
Neurocrine Biosciences Reports Positive Phase 2 Results for Osavampator in Major Depressive Disorder
Neurocrine Biosciences; osavampator; Phase 2 results; major depressive disorder; AMPA-PAM; SAVITRI study; clinical trial; adjunctive treatment; depression; safety profile
AbbVie’s Rinvoq Achieves Second Phase 3 Win in Alopecia Areata Trials
AbbVie; Rinvoq; upadacitinib; alopecia areata; Phase 3 clinical trial; hair regrowth; SALT score; eyebrows; eyelashes; safety profile
Novartis plans global filings after ianalumab hits primary endpoints in two Phase 3 Sjögren’s disease trials
Novartis; ianalumab; BAFF‑R; B-cell depletion; Sjögren’s disease; NEPTUNUS-1; NEPTUNUS-2; ESSDAI; Phase 3; regulatory filings; first targeted treatment; safety profile
Assembly Bio Reports Phase 1b Success in Herpes; Gilead Increases Stake with 2.3M Shares
Assembly Bio; Phase 1b trial; ABI-5366; herpes simplex virus (HSV-2); viral shedding reduction; genital lesion reduction; safety profile; Gilead Sciences; collaboration; stock purchase
ImmuneOnco and Instil Bio’s PD-L1xVEGF Bispecific Antibody Shows Promising Results in Phase 2 Lung Cancer Trial
ImmuneOnco; Instil Bio; IMM2510/AXN-2510; PD-L1xVEGF bispecific antibody; NSCLC; Phase 2 clinical trial; response rate; safety profile; chemotherapy combination; lung cancer
Avidity’s Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment
Del-zota, Duchenne muscular dystrophy (DMD), RNA therapeutics, exon 44 skipping, dystrophin production, creatine kinase reduction, safety profile